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Protein kinase B/Akt has been described as a central mediator of anti-apoptotic signals transduced by the PI3 kinase. Although
the role of Akt in the suppression of apoptosis is well elucidated, a potential function of Akt in tumorigenesis and
chemoresistance is less intensively documented. In this study, we describe the construction of a novel form of constitutively
active Akt1, which relies on the deletion of its pleckstrin homology domain and the insertion of a C-terminal farnesylation
sequence. Stable cell lines were generated with MCF10A mammary epithelial cells and A549 human NSCLC cells expressing
constitutively active Akt1. Enigneered MCF10A cells were rendered resistant towards apoptosis resulting from loss of cellular
substrate attachment (anoikis). We investigated the chemosensitivity of A549 cells expressing farnesylated Akt vs control cells.
A profoundly decreased sensitivity towards Mitoxantrone and cisplatin was observed in cells expressing farnesylated Akt. No
signiﬁcant difference in sensitivity however was observed upon treatment with cell cycle speciﬁc chemotherapeutic agents like
paclitaxel. Our data suggest, that Akt is a central mediator in the suppression of anoikis and modulation of chemotherapy-
induced apoptosis. Therefore it represents a promising target for small molecule inhibitors to shift the apoptotic threshold in
cancer cells after treatment with standard chemotherapy.
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A prerequisite of transformed cells in order to form solid
tumours is the acquisition of growth properties that allow them
to divide indeﬁnitely and in an uncontrolled fashion. During the
process of malignant transformation which requires molecular
alterations like activation of proto-oncogenes, and suppression
of tumour-suppressor genes, tumour cells have to thrive under
conditions of low oxygen and poor nutrient supply. Such condi-
tions would normally lead to the onset of programmed cell
death to eliminate potentially dangerous cells from the organism.
Tumour cells must therefore have acquired molecular mechan-
isms to counteract apoptotic triggers in order to survive under
unfavourable conditions and to be able to form solid tumours.
It is assumed that mechanisms responsible for anti-apoptotic
signalling might be equally important for the development of
the pathological cancer phenotype as proliferative signalling
cascades.
One pathway that has been shown to mediate important
survival signals for mammalian cells comprise receptor tyrosine
kinases like PDGFR or IGF-1R (Franke et al, 1995; Kohn et
al, 1995) that activate the PI3 kinase upon binding of their
respective ligands. Activation of phosphatidyl-inositol 3-kinase
(PI3K) protects cells from apoptosis and is hence considered a
survival signal. The phosphatidylinositide lipids produced by
PI3K can stimulate multiple kinases, including protein kinase
B/Akt, which is a central downstream mediator of anti-apoptotic
signals transmitted by PI3K (Datta et al, 1999). The amino
terminus of Akt contains a PH domain that recruits the protein
to the cell membrane by binding to the PI3K product PI(3, 4,
5)P3 and PI(3, 4,)P2 leading to a conformational change (Alessi
and Cohen, 1998). This conformational change allows Akt to be
phosphorylated at threonine 308 and serine 473 by the kinases
PDK1 and a postulated kinase PDK2. A number of potential
substrates within the apoptotic machinery have been identiﬁed
that are phosphorylated by Akt within the consensus sequence
RXRXXS/T (Obata et al, 2000). The ﬁrst Akt substrate identiﬁed
was glycogen synthase kinase 3 (GSK3) (Cross et al, 1995). Phos-
phorylation of GSK3 at serine 9 results in its inactivation.
Besides regulating glycogen synthesis, GSK3 is involved in the
regulation of several intracellular signalling pathways including
AP1 (Scalia et al, 2001), CREB (Cross et al, 1995), and the
tumour suppressor gene product APC (Zumbrunn et al, 2001).
Phosphorylation of the pro-apoptotic protein Bad at serine 136
by Akt creates a binding site for 14-3-3 proteins and thereby
prevents Bad from binding and inhibiting the anti-apoptotic
protein Bcl-xL (Datta et al, 1997). Similarily, phosphorylation
of the forkhead transcription factor FKHRL1 by Akt at threonine
32 and serine 253 creates a binding motif for 14-3-3 proteins
resulting in cytoplasmic retention of FKHRL1 (Brunet et al,
1999). Transcriptional targets of protein kinase B/Akt (PKB/
Akt) include the pro-apoptotic proteins like Fas resulting in
transcriptional downregulation dependent on activated Akt (Peli
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www.bjcancer.comet al, 1999). Caspases are intracellular proteases that function as
initiators and effectors of apoptosis. Akt directly phosphorylates
caspase-9 at serine 196 and inhibits its protease activity (Cardone
et al, 1998). Activation of the NF-kB pathway by Akt has been
demonstrated by the direct association of Akt with IKK. In vitro
phosphorylation of IKK by Akt is supposed to enhance the
degradation of IkB and consequently the translocation of NF-
kB into the nucleus (Ozes et al, 1999). However, results from
these in vitro kinase assay have not been conﬁrmed (Delhase et
al, 2000). Other substrates of Akt include apoptosis signal-regu-
lating kinase 1 (Kim et al, 2001), phosphofructokinase 2 (Deprez
et al, 1997), Mdm2 (Mayo and Donner, 2001) and endothelial
NO synthase (Dimmeler et al, 1999). The dominant negative
caspase-8 homologue c-FLIP is upregulated in tumour cell lines
on a transcriptional level by the PKB pathway through a yet
unknown mechanism (Panka et al, 2001). In vivo, targeted
disruption of Akt2 leads to insulin resistance and mild diabetes
mellitus-like syndrome (Cho et al, 2001a). The metabolic
abnormalities resulting from Akt2 deﬁciency could not be
compensated by Akt1 or Akt3, reﬂecting differences in the
substrate speciﬁcity, relative abundance in insulin-responsive
tissues, or both. Non redundant functions of Akt isoforms were
further emphasised by targeted deletion of Akt1. These animals
display a conspicuous impairment in organismal growth, but
no defects in glucose meatbolism (Cho et al, 2001b).
Besides playing a role in insulin signalling and in mediating
anti-apoptotic stimuli triggered by multiple exogenous stimuli,
Akt has been shown to be overexpressed in a variety of human
tumour cell lines and cancers (Bellacosa et al, 1995; Ringel et al,
2001; Roy et al, 2002) and to be a mediator of oestrogen resis-
tance in breast cancer cells (Campbell et al, 2001). Moreover,
Akt activity can be deregulated by constitutive activation or by
inhibition of PTEN/MMAC1, a phosphatase that directly coun-
teracts Akt through the dephosphorylation of PI-3-, 4-, 5-P3
(Stambolic et al, 1998). Overexpression of activated Akt can
suppress anoikis, which is the induction of apoptosis after
detachment of epithelial cells from extracellular matrix (Ryto ¨maa
et al, 2000).
Due to its potent capacities as modulator of anti-apoptotic
tumour cell signalling Akt is discussed as a potential target for
small molecule kinase inhibitors. These are expected to shift the
apoptotic threshold in cancer cells after treatment with
chemotherapy and might be a way in counteracting the effects
of loss of the tumour suppressor PTEN, which normally acts to
inhibit PKB.
Despite the fact that Akt has been intensively studied in anti-
apoptotic signalling and has been shown to be overexpressed in
various types of cancer, relatively few data support the role of
Akt in downregulating the sensitivity of cancer cells towards stan-
dard chemotherapy (Page et al, 2000; Hayakawa et al, 2000). To
further explore the role of Akt in modulating chemotherapy or
matrix-detachement-induced apoptosis, we designed a novel form
of a constitutively active Akt1: we deleted the N-terminal PH
domain, which is responsible for membrane attachment and
subsequent activation and inserted a C-terminal sequence tag
encoding a farnesylation motif and a stretch of basic amino acids
to target Akt1 to the membrane. Deletion of the PH domain
unmasks the residues mandatory for activation by phosphoryla-
tion (Alessi and Cohen, 1998) and the ectopically expressed
protein can be released from the membrane by cellular farnesyl
esterases. With this Akt1-construct we generated stable cell clones
of MCF10A mammary epithelial cells and A549 non small cell
lung cancer (NSCLC) cells expressing constitutively active farnesy-
lated (CA) Akt1. Here we describe the effects of CA-Akt on the
suppression of anoikis and modulation of chemosensitivity
towards a panel of chemotherapeutic agents currently used in
the clinic.
MATERIALS AND METHODS
Materials
Anti-Akt and anti-phospho-Akt antibodies were obtained from Cell
Signalling Technology, Inc. (Beverly, MA, USA); M2 anti-FLAG anti-
body, b-actin antibody, and all other reagents were purchased from
Sigma Chemical (St. Louis, MO, USA) unless otherwise speciﬁed.
Cells and cell culture
A549 human lung cancer cells were obtained from the National
Cancer Institute (Frederick, MD, USA) and were maintained in
Ham’s F12 medium supplemented with 10% FBS, 100 u ml
71
penicillin G, and 100 mgm l
71 streptomycin. MCF10A human
mammary epithelial cells (ATCC) were maintained in DMEM:F12
medium supplemented with 5% horse serum, 0.5 mgm l
71 hydro-
cortisone, 10 mgm l
71 insulin, 5 nM EGF, 100 u ml
71 penicillin G,
and 100 mgm l
71 streptomycin.
Construction of the pcDNA vectors containing farnesylated
Akt1 devoid of the PH domain
RNA was prepared from MCF10A cells using the RNeasy kit from
Qiagen (Hilden, Germany). Subsequently the RNA was transcribed
into cDNA with the ﬁrst strand cDNA kit from Roche Diagnostics
(Indianapolis, IN, USA) using an oligo-dT primer as supplied by
the manufacturer. Human Akt1 devoid of its PH domain was
ampliﬁed by PCR using the forward primer 5'-AAGGACGACGAC-
GACCTGGAATTCGCTGACGGCCTCAAGAA-3' and the backward
primer 5'-CTTGCTCTTCTTCTTCTTCTTCTTTCTAGAGGCGCT-
GCTGCTGGC-3'. In a second round of PCR the resulting fragment
was ampliﬁed with the forward primer 5'-ATGCTAGCGCCAC-
CATGGACTACAAGGACGACGACGAC-3' and the backward
primer 5'-TATGTTTAAACTCACATGATCACGCACTTGGTCTT-
GCTCTTCTTCTT-3'. The ﬁnal PCR product encoded Akt1 devoid
of its PH domain (aa 1–106) with an N-terminal fusion of the
FLAG antibody epitope and a C-terminal fusion of a poly-basic tail
and a farnesylation sequence. The PCR fragment was subcloned
into pcDNA 3.1 Hygro and pcDNA6 vectors via the restriction sites
NheI and PmeI included in the polylinker of the vector and the
respective PCR primers.
Establishment of farnesylated Akt1 expression clones in
MCF10A and A549 cells
Transfection was performed with the Fugene-6 transfection kit
(Roche Diagnostics, Indianapolis, IN, USA) according to the
manufacturer’s recommendations. Stable MCF10A clones trans-
fected with the pcDNA3.1 Hygro derivative were selected in
medium containing 20 mgm l
71 Hygromycin B (Roche Diagnos-
tics, Indianapolis, IN, USA), A549 clones transfected with the
pcDNA6 derivative were selected in growth medium supplemented
with 70 mgm l
71 Blasticidin S (Invitrogen, Carlsbad, CA, USA).
Stable clones were analysed for expression of ectopic FLAG-tagged
Akt1 devoid of its PH domain and containing the farnesylation
sequence by immunoblotting with the M2 antibody speciﬁc for
the FLAG-tag. Clones that were both, resistant towards the respec-
tive antibiotic and positive on protein level, were selected for
further studies. Clones expressing farnesylated Akt1 were named
A549-Akt1 or MCF10A-Akt1, respectively. Experiments were
conducted with at least two different clones.
Cytotoxicity assay
Cells were seeded onto 96-well culture plates and incubated in
100 ml growth medium supplemented with 0.5% FCS. After 24 h
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as indicated in 50 ml volume. Seventy-two hours after addition of
the drugs cell viability was assayed by adding 75 ml of 1 mg ml
71
XTT (sodium 3'-[1-(phenyl amino carbonyl-3,4-tetrazolium]-bis
(4-methoxy-6-nitro-) benzene sulphonic acid) in RPMI containing
7.66 mgm l
71 PMS (N-methyl dibenzopyrazin methyl sulphate).
After incubating the cells for 3 h at 378Ci naC O 2 incubator, cell
viability was then determined by measuring the optical absorbance
at a wavelength of 490 nm and normalisation with the correspond-
ing control cells treated with 1% DMSO.
Immunoblot analysis
Cells were lysed in a lysis buffer containing 50 mM Tris, pH 7.4,
150 mM NaCl, 1% NP-40, 50 mM NaF, 1 mM Na3VO4,1 m M
phenylmethylsulphonyl ﬂuoride. The lysates were cleared by centri-
fugation and the supernatants were collected. Equal amounts of
lysate protein were used for Western blot analysis with antibodies
as indicated. Speciﬁc signals were visualised by use of the ECL
chemoluminescence detection kit (Amersham, Braunschweig,
Germany).
Determination of Akt1 phosphorylation
Cells were seeded out in 6-well plates and switched to medium
containing 0.5% serum after attachment. After starvation overnight
the cells were stimulated for 15 min. with medium containing 10%
serum or medium additionally supplemented with a cocktail
containing each 10 ng ml
71 of EGF, PDGF, and IGF-1. Cell lysates
were then analysed in immunoblot assays with antibodies from Cell
Signaling Technologies (Beverly, MA, USA) speciﬁc for phospho-
Akt (Thr 308) or phospho-Akt (Ser 473). Signals were visualised
by use of the ECL chemoluminescence detection kit (Amersham,
Braunschweig, Germany).
Akt kinase assay
The Akt kinase assay was performed using the Akt Kinase Assay Kit
from Cell Signalling Technology, Inc. with GSK-3 fusion protein as
substrate. Cells were seeded out in 10 cm dishes and switched to
medium containing 0.5% serum after attachment. After starvation
overnight the cells were either kept unstimulated or were stimu-
lated for 20 min with medium containing 10% foetal calf serum
(FCS) supplemented with a cocktail containing each 10 ng ml
71
of EGF, PDGF, and IGF-1. After cell lysis and clariﬁcation by
centrifugation, the lysates were swirled for 3 h at 48C with an anti
Akt-agarose conjugate (control transfected cells) or with an anti
M2-Flag-agarose conjugate (cells expressing farnesylated Akt1).
After three times washing with lysis buffer and with kinase buffer
the immunoprecipitates were subjected to an in vitro kinase reac-
tion with 40 ml of reaction mixture containing kinase reaction
buffer supplemented with 200 mM ATP and 1 mg GSK-3-fusion
protein. The reaction was allowed to process at 308C for 30 min
and stopped by boiling the samples in SDS sample buffer for
5 min; the products were separated by 12.5% SDS–PAGE. Immu-
noprecipitates were then analysed in immunoblot assays with
antibodies speciﬁc for phospho-GSK (Ser 21/9) and Akt. Signals
were visualised with the the ECL chemoluminescence detection
kit (Amersham, Braunschweig, Germany).
Induction of anoikis
To prevent cell attachment, tissue culture plates were coated twice
with a solution of 5 mg ml
71 poly-HEMA (Sigma, St. Louis, MO,
USA), dried and rinsed with PBS. The cells were subsequently added
into the plates in medium as indicated in the experiments and
induction of apoptosis through loss of cell attachment was measured
after 24 h of incubation at 378C (Frisch and Francis, 1994).
Quantitation of apoptosis by ELISA
To detect the onset of apoptosis in the target cells, an apoptosis
detection ELISA kit (Roche Diagnostics, Indianapolis, IN, USA)
was used according to the manufacturer’s instructions. This
photometric enzyme immunoassay quantitatively measures cyto-
plasmic histone-associated DNA fragments (mononucleosomes
and oligonucleosomes), that are characteristic of apoptotic cell
death. Triplicate aliquots of 10
4 cells well
71 were seeded in 96-
well plates and treated as indicated. After incubation for 24 h at
378Ci n5 %C O 2 and 95% humidiﬁed air, the apoptosis assay
was then carried out according to the manufacturer’s instructions
to quantify cytoplasmic histone-associated DNA fragments. Opti-
cal absorbance was measured at a wavelength of 405 nm in a
microplate reader.
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B
Figure 1 Construction of a farnesylated constitutively active Akt1 expression vector. (A) While wildtype Akt1 depends on its PH domain for membrane
attachment and subsequent phosphorylation at Thr 308 by PDK1 and Ser 473 by a postulated PDK2 (left), the expression construct described herein is
devoid of the PH domain and contains a C-terminal farnesylation tag that is supposed to alleviate membrane dislocation after activation. (B) Schematic
presentation of the farnesylation sequence including a poly-basic tail for energetically favored membrane attachment. F, sequence encoding the FLAG
tag for antibody detection.
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To investigate the role of Akt in the modulation of the onset of
anoikis and of chemosensitivity in cancer cells we designed a
novel form of constitutively active Akt1. Membrane attachment
is a prerequisite for Akt to become activated by phosphorylation
at threonine 308 and serine 473. In wild type Akt this recruitment
to the membrane is mediated by binding of the PH domain to
the membrane anchor PIP3 generated by the PI3K. The subse-
quent conformational change opens the catalytic domain and
renders the kinase accessible for phosphorylation, which is a
prerequisite for constitutive activation. Expression vectors for
constitutively active Akt are described, that accomplish membrane
insertion by an N-terminal myristylation tag that attaches the
protein to the membrane (Franke et al, 1997). However, protein
myristylation is a covalent process and membrane insertion is
irreversible due to the lack of enzymes capable of cleaving the
protein myristylation. To avoid potentially hampered membrane
dislocation in a constitutively active derivative of Akt, we designed
an expression vector that encodes for human Akt1 devoid of its
PH domain and fused with an C-terminal farnesylation sequence
linked to a polybasic tail (Resh, 1994). A schematic representation
this constitutively active farnesylated form of Akt1 is shown in
Figure 1.
Functional characterisation of ectopically expressed
farnesylated Akt1
MCF10A human mammary epithelial cells and A549 human
NSCLC cells were stably transfected with the expression vector
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Figure 2 (A) Expression and constitutive activation of farnesylated Akt1 in A549 NSCLC cells and MCF10A mammary epithelial cells. Control transfected
A549 and MCF10A cells, respectively or cells expressing farnesylated Akt1 (as indicated) were serum starved overnight and then stimulated for 15 min with
medium containing 10% FCS (S) or 10% FCS plus a cocktail of 10 ng ml
71 each EGF, IGF-1, and PDGF (GF). Cell lysates were analysed by immunoblotting
with antibodies speciﬁc for Akt1, FLAG-epitope, phospho-Akt (Thr 308) or phospho-Akt (Ser 473) as indicated. The ectopically expressed farnesylated
Akt1 devoid of the PH domain migrates at a Mr of approximately 50 kDa. (B) Kinase activity of endogenous and ectopically expressed farnesylated
Akt. Cells were serum starved for 16 h and then stimulated as described above. Immunoprecipitates of endogenous Akt from control transfected cells
and farnesylated Akt from transfected cells were used in kinase assay reactions with GSK-3-fusion protein as substrate. Immunoblots were assayed with
antibodies speciﬁc for phospho-GSK (Ser 21/9) (lower portion) and Akt (upper portion). Positions of phosphorylated GSK-fusion protein and Akt1 are
indicated by an arrow.
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were tested positive for ectopic expression of Akt1 by reactivity
of the lysates with the M2 anti-FLAG antibody (MCF10A-Akt1
or A549-Akt1) were used in this study. To analyse whether the
membrane targeting by a farnesylation tag renders ectopically
expressed Akt1 constitutively active, the phosphorylation status of
threonine 308 and serine 473 was determined in transfected cells
as a marker of kinase activation (Alessi and Cohen, 1998).
MCF10A-Akt1 and A549-Akt1 cells were seeded out in growth
medium. After attachment the cells were serum starved for 16 h
and then stimulated with medium containing 10% serum or
10% serum plus growth factors (EGF, PDGF, and IGF-1). Lysates
were then analysed in immunoblot assays with antibodies speciﬁc
for phospho-Akt (Thr 308) or phospho-Akt (Ser 473). Cells trans-
fected with the empty vector were used as controls. The results are
shown in Figure 2A: while endogenous Akt was detected as a
protein migrating at a Mr around 66 kDa, ectopically expressed
Akt was detected with both, anti-Akt1 anti-FLAG antibodies as a
protein with an obvious Mr of about 50 kDa. Endogenous Akt1
phosphorylation at Thr 308 and Ser 473 was only detectable after
stimulation of the cells with a growth factor cocktail and, to a
lesser extent, with serum. In contrast, farnesylated Akt1 was phos-
phorylated irrespective of serum conditions or growth factor
stimulation.
To determine the kinase activity of endogenous and of ectopi-
cally expressed farnesylated Akt1 in MCF10A and A549 cells we
performed an in vitro kinase assay with GSK-3-fusion protein as
substrate. After attachment cells were serum starved for 16 h and
then either kept untreated or were stimulated with medium
containing 10% serum plus growth factors (EGF, PDGF, and
IGF-1). Akt kinase activity was determined in an in vitro kinase
assay as described in Materials and Methods. The results are shown
in Figure 2B: in MCF10A cells endogenous Akt displayed a consid-
erably lower kinase activity under low serum conditions as
compared to conditions after stimulation with 10% serum and
growth factors. Ectopically expressed farnesylated Akt1 showed
comparable kinase activity under both stimulation conditions.
Similar results were obtained in A549 cells. However, in these cells,
the kinase activity of farnesylated Akt could still be enhanced by
short incubation with 10% FCS and the growth factor cocktail.
The results from the in vitro kinase assays and from phospho-
Akt speciﬁc analysis show that removal of the PH domain and
fusion of a farnesylation sequence to the C-terminus sufﬁces to
activate ectopically expressed Akt1 to obtain high levels of kinase
activity.
Suppression of anoikis upon expression of farnesylated
Akt1
Untransformed cells commonly undergo programmed cell death
after detachment from the extracellular matrix. This type of apop-
tosis has been termed anoikis (Frisch and Francis, 1994). Tumour
cells must have evolved strong mechanisms for the suppression of
anoikis in order to disintegrate from their original cellular environ-
ment, to extravasate and to form distant metastases. As matrix
binding to cell surface integrins normally transmits a cell survival
signal through the activation of the PI3K (Khwaja et al, 1997),
we analysed whether expression of farnesylated Akt1 is able to
suppress anoikis in MCF10A immortalised mammary epithelial
cells.
The cells were seeded in high volume (3 ml) in 6-well plates in
order to provide conditions that prevent the cell attachment before
the onset of anoikis. Twenty-four hours later the cells were
analysed microscopically and pictures were taken under the differ-
ent medium conditions. The results are shown in Figure 3.
Cultivation of control transfected MCF10A cells (upper panel) in
medium containing 0.5% serum without other supplements led
to the onset of phenotypic markers of anoikis (left). MCF10A-
Akt1 cells (lower panel) however, did not undergo anoikis under
these medium conditions (left). Addition of insulin and EGF
(middle column) or full medium (right column) suppressed the
characteristics of anoikis in both, control transfected, and
MCF10A-Akt1 cells.
An apoptosis ELISA that detects cytoplasmic histone-associated
DNA fragments was performed to conﬁrm that the phenotypic
markers of anoikis coincide with molecular markers of apoptosis.
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
MCF10A
MCF10A-Akt1
0.5% FCS 0.5% FCS+ EGF Growth medium
+ insulin
Figure 3 Suppression of anoikis in MFC10A cells expressing constitutively active Akt1. MCF10A control cells (upper panel) and MCF10A-Akt1 cells were
seeded in 6-well plates in 3 ml of medium containing 0.5% horse serum (left), 0.5% horse serum plus EGF and insulin (middle panel), or normal growth
medium (right panel). Microscopic pictures were taken 24 h post seeding.
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attachment. Control transfected MCF10A cells and MCF10A-Akt1
cells were cultured in coated plates under medium conditions as
shown in Figure 4 and subsequently analysed for molecular features
of apoptosis. Control transfected MCF10A cells were found to
undergo apoptosis in poly-HEMA coated plates if grown in
medium containing low serum without supplement of growth
factors. Apoptosis could only be prevented by the addition of insu-
lin or EGF, or full medium. MCF10A-Akt1 cells in contrast were
resistant towards apoptosis under any of the conditions chosen
in this experiment. The experiments were conﬁrmed with two
independent clones. The data from these experiments show that
MCF10A cells still harbour the ability to undergo apoptosis upon
loss of matrix detachment under the appropriate conditions.
Expression of constitutively active farnesylated Akt1 alone is sufﬁ-
cient to efﬁciently suppress anoikis. Moreover, these results
indicate that farnesylated Akt1 not only is phosphorylated at the
positions described to be mandatory for full activity, but also exerts
biological function when stably transfected in mammalian cells.
Chemoresistance of A549 human lung cancer cells
expressing farnesylated Akt1
Intrinsic or acquired resistance towards chemotherapy is the most
important limitation of current treatment options in cancer. While
active transport mechanisms have been described to shufﬂe
chemotherapeutic agents out of cells, other mechanisms are
suggested that effectively suppress apoptotic pathways in tumour
cells. Although Akt has been described in the suppression of a vari-
ety of apoptotic stimuli, relatively little is known about the
modulation of chemosensitivity by Akt1. We therefore compared
the chemosensitivity of control transfected A549 human NSCLC
cells vs A549 cells expressing farnesylated Akt1 towards a regimen
of clinically applied chemotherapeutics. The viability of the cells
after incubation with the substances for 72 h was determined with
a standard XTT assay as described in Materials and Methods. A549
cells expressing constitutively active Akt1 displayed an approxi-
mately 10-fold decreased sensitivity towards the DNA alkylating
agent Mitoxantrone as compared to control cells (IC50 0.2 mM vs
0.02 mM, respectively). A more than two-fold decreased sensitivity
was observed upon treatment of the cells with the DNA alkylating
agent cis-platin (Figure 5). Interestingly, no altered chemosensitiv-
ity was observed with the M-phase speciﬁc tubulin inhibitor
paclitaxel. A three-fold decreased sensitivity of A549-Akt1 cells
was observed towards 5-ﬂuorouracil. However, the cytotoxicity
even at the highest concentrations did not exceed 70% of untreated
control cells. It is noteworthy to mention that a differential
chemoresistance was only observed when the cells were cultured
in medium containing low serum. Under normal serum conditions
the activation of endogeneous Akt probably sufﬁces to render both
cell lines more chemoresistant irrespective of ectopic expression of
constitutively active Akt.
The IC50 values towards the various chemotherapeutics are
summarised in Table 1. No difference was observed upon treat-
ment with doxorubicin. At lower doses the anthracyclin
doxorubicin has been described as an inhibitor of DNA topoisome-
rase 1, while at higher concentrations it can intercalate with DNA.
Interestingly, in MCF10A cells expressing farnesylated Akt1 we
found a marked decrease in sensitivity towards both, cisplatin
and doxorubicin, but consistently not towards paclitaxel (data
not shown).
From these data we conclude, that the expression of activated
Akt1 in A549 human NSCLC cells can cause partial resistance
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Figure 4 Suppression of anoikis in MFC10A cells expressing constitu-
tively active Akt1. MCF10A control cells and MCF10A-Akt1 cells were
seeded in poly-HEMA coated plates to prevent cell attachment under
medium conditions as indicated in the ﬁgure. Sixteen hours later the cells
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Figure 5 Chemoresistance of A549 human lung cancer cells expressing farnesylated Akt1. Control transfected A549 cells or A549-Akt1 cells were
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or mitoxantrone (right) as indicated and incubated for another 72 h at 378C. Cell viability was then determined with a standard XTT assay as described in
Materials and Methods. Values are the mean of at least three independent experiments.
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tive agents, but in our system does not alter the sensitivity
towards cell cycle (M-phase) speciﬁc chemotherapeutics like
paclitaxel.
DISCUSSION
In this study, we investigated the inﬂuence of constitutively acti-
vated PKB/Akt1 on the onset of apoptosis in MCF10A
immortalised mammary epithelial cells as measured by protection
from anoikis and on the chemosensitivity of A549 human NSCLC
cells. For these studies we utilized an expression vector encoding
Akt1 devoid of its PH domain and a C-terminally fusion of a
farnesylation sequence. Activation of farnesylated Akt was deter-
mined by analysing the phosphorylation status of the ectopically
expressed Akt at Thr308 and Ser473 as well as by in vitro kinase
assays. While we observed phosphorylation of the farnesylated
Akt at both sites in MCF10A cells under low serum conditions,
the phosphorylation of these amino acids was less well pronounced
in A549 cells. However, immunoprecipitated farnesylated Akt was
shown in in vitro kinase assays to be highly active in both cell lines.
Surprisingly, the kinase activity of farnesylated Akt in A549 cells
could further be stimulated by growth factors. We explain this
by the fact that activation of Akt requires the phosphorylation at
Thr308 by PDK1. In these cells, the activity of PDK1, which can
be stimulated by growth factors through the generation of phos-
phoinositol trisphosphates (Currie et al, 1999) may be the rate
limiting step for activation of both, endogenous and ectopically
expressed Akt.
We were able to demonstrate that farnesylated Akt1 was a very
potent inhibitor of anoikis in MCF10A immortalised human
mammary epithelial cells. We selected this cell line, since it still
retains the capacity to undergo apoptosis upon loss of substrate
attachment. In this context we investigated the involvement of
focal adhesion kinase (FAK) in the suppression of anoikis (Frisch
et al, 1996). However FAK was not found to be phosphorylated
or active to a higher degree in MCF10A-Akt1 cells as compared
to control cells (data not shown). We therefore assume that
enhanced FAK activity does not play a major role in the prevention
of anoikis in this cellular system. Our results with MCF10A cells
are in agreement with data from Ryto ¨maa et al (2000) who were
able to prevent anoikis of early passages of Madin-Darby canine
kidney cells (MDCK) by activated ras (V12 mutation) or PKB.
These data together with our chemosensitisation studies indicate,
that Akt may have a dual role in tumorigenesis: Early in the
process of malignant transformation Akt may prevent anoikis when
immortalised cells leave their original cellular context to extravasate
into a different environment and later to protect cancer cells from
unfavourable conditions of e.g. poor nutrient supply and low
oxygen to transmit strong survival signals. The clinical consequence
ﬁnally would be reﬂected in a signiﬁcantly reduced chemosensitiv-
ity of cancers with an activated Akt pathway. However, it has to be
emphasised that multiple factors such as overexpression of multi-
drug transporter proteins, host derived factors or other failures
in the apoptotic machinery (e.g. loss of caspase or Apaf-1 expres-
sion (Soengas et al, 2001; Tannock, 2001) signiﬁcantly contribute
to the frequent failure of chemotherapy in the clinic.
Surprisingly, although a wealth of information exists describing
the role of Akt in conveying survival signals, only relatively few
data are published describing an association of Akt activation
and/or overexpression with chemoresistance. Page et al (2000)
observed a 30% decreased sensitivity of Caov-3 human ovarian
cancer cells expressing activated Akt at 10 mM paclitaxel. Mechan-
istically they explained their observation by an inhibition of
cytochrome c release from mitochondria of cells expressing acti-
vated Akt. Yuan et al (2000) observed elevated Akt2 activity in
36% of analysed human ovarian cancer specimen. The majority
of tumours with elevated Akt activity were graded stage III and
IV. Interestingly, high PI3K levels did not necessarily correlate with
Akt activation. This observation could explain the data of Mitsuu-
chi et al (2000), who did not observe altered drug sensitivity
towards cisplatin and paclitaxel upon inhibition of the PI3K path-
way by LY294002 in A2780 ovarian cancer cells. Another indirect
link to the involvement of Akt in tumorigenesis stems from the
observation that the tumour suppressor PTEN/MMAC1 is a direct
counteractor of Akt activation by dephosphorylating the 3' position
of the membrane anchor PI 3,4,5-trisphosphate (Stambolic et al,
1998).
In this study we compared the sensitivity of A549 cells
expressing constitutively active Akt1 towards ﬁve different
chemotherapeutic agents. A profound desensitisation in cells
expressing activated Akt1 as compared to control transfected cells
was observed with Mitoxantrone and cisplatin. Similar data have
also been obtained with MCF10A cells (data not shown). Both
of these agents can exert their cytotoxic mode of action by indu-
cing DNA damage irrespective of the cell cycle stage.
Mitoxantrone has been described to intercalate with DNA, but
also to target Topoisomerase II and to interrupt its catalytic cycle
thereby leading to persistant double strand breaks of DNA
(Boland et al, 2000). Furthermore, Mitoxantrone treatment of
cells has also been shown to induce the transcription factor NF-
kB, which then initiates the transcription of several anti-apoptotic
genes and also of the gene for the inhibitor of kB kinase (IKK)
(Engels et al, 2000). A possible mechanism for chemoresistance
towards Mitoxantrone mediated by constitutively active Akt might
be the phosphorylation of IKK by Akt, which enhances the degra-
dation of IkB and consequently the translocation of NF-kB into
the nucleus (Ozes et al, 1999). Cisplatin has been described to
lead to activation of Caspase 8 with subsequent initiation of the
proteolytic caspase cascade (Micheau et al, 1999a,b; Engels et al,
2000). A possible mechanism for the chemoresistance mediated
by constitutively active Akt might be a down-regulation of
FADD-Protein or the upregulation of the caspase 8 inhibitor c-
FLIP (Panka et al, 2001). In contrast, no modulation of chemo-
sensitivity was seen with chemotherapeutic agents that function
only in a speciﬁc phase of the cell cycle, like paclitaxel that only
targets cells in mitosis. Paclitaxel differs from cisplatin or Mitox-
antrone in its mechanism of action. Unlike cisplatin or
Mitoxantrone, that target the DNA and induce strong DNA
damage responses, paclitaxel is a spindle poison that induces a
mitotic arrest by excessively stabilising the microtubules (Crossin
and Carney, 1981) responsible for chromosomal segregation. No
pathways are described to date in which Akt1 can interfere to
prevent the induction of apoptosis after disruption of the spindle
apparatus with subsequent mitotic arrest. Doxorubicin at lower
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Table 1 Chemosensitivity of control transfected A549 cells or A549-
Akt1 cells. Values were determined from at least three independent experi-
ments performed as quadruplicates.
A549
IC50 IC50 Resistance
Compound (wt) (Akt1) factor
5-FU 10* 30* 3*
Cisplatin 2 5 2.5
Doxorubicin 0.4 0.4 1
Paclitaxel 0.0008 0.00105 1.3
Mitoxantrone 0.02 0.2 10
The resistance factor was calculated as the IC50 of A549-Akt1 cells divided by the
IC50 of control transfected A549 cells. *The maximum killing observed with 5-fluor-
uracil was 50%. The results for this compound were therefore not considered as true
IC50 values.
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its mechanism of action in a cell cycle-dependent manner. At
higher concentrations Doxorubicin intercalates with the DNA
leading to strand breaks in a non cell cycle-dependent fashion
(Ross and Bradley, 1981; Bodley et al, 1989). Thus, the cytotoxi-
city of Doxorubicin at lower concentrations is cell cycle
dependent, while at higher concentrations it can also kill cells that
are not actively progressing through the cell cycle (Schmidt et al,
2001). It will be interesting to study in detail the molecular
mechanisms downstream of Akt1 that mediate chemoresistance
towards Mitoxantrone and cisplatin.
In summary, we could show that the expression of an activated
form of Akt1 can confer resistance of immortalised epithelial cells
towards apoptosis induced by loss of substrate attachment and can
induce chemoresistance towards certain classes of chemotherapeu-
tic agents like cisplatin or Mitoxantrone. These data further
emphasise that Akt1 may be a well suited target for directed
tumour therapy at both, early and advanced stages of tumorigen-
esis to prevent spreading of the disease and to resensitise
established tumours for standard chemotherapy.
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